- Posts: 1127
- Thank you received: 276
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
onlinelibrary.wiley.com/doi/10.1111/ejh.12733/abstract
Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series
Authors: Monica Carpenedo, Silvia Cantoni, Veronica Coccini, Enrico Maria Pogliani, Roberto Cairoli
First published: 4 February 2016 DOI: 10.1111/ejh.12733
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts resulting from both immune-mediated platelet destruction and inappropriate bone marrow platelet production. Therefore, in patients with ITP failing immunosuppressants/splenectomy, an alternative approach is to enhance platelet production stimulating thrombopoiesis. Studies on the development of recombinant thrombopoietins (rhTPO) were halted as a minority of patients developed an autoantibody that neutralized pegylated rhTPO and also cross-reacted with and neutralized endogenous TPO resulting in thrombocytopenia. Clinical use of romiplostim, a second-generation TPO-RAs, has shown that during long-term treatment, it may elicit the development of neutralizing antibodies to this agent resulting in acute thrombocytopenia. In our case series of 47 primary adult patients with ITP treated with romiplostim, 28 of 47 are evaluable for response loss. Among these, we observed eight patients who either progressively (3 ofor abruptly (5 of
lost response which accounts for a prevalence of 28.5%. Neutralizing antibody testing could be performed in 4 of 8 patients and 3 of 4 tested positive. These antibodies did not cross-react with endogenous TPO and retesting of 2 patients at 9 and 7 months yielded a negative result. At follow-up, 5 of 8 patients – including the 3 patients with neutralizing antibodies – went into long-term complete response when switched to a different therapy while 3 of 8 patients never regained a response on subsequent lines of therapy. Response loss does not seem to be so rare an event during romiplostim administration (28.5% in our series) and in a minority of patients, it can be associated with development of drug neutralizing antibodies. Although recognized by the manufacturer as a possible adverse event ensuing during romiplostim administration, development of neutralizing antibody in everyday clinical practice has so far not been specifically addressed in reports on romiplostim use outside controlled studies. Unfortunately, testing for these antibodies requires adhesion to strict procedures which is not easily accomplished in everyday clinical practice. This complexity represents a significant drawback in extending antibody testing to all patients who lose response to romiplostim.
Margaret k wrote: Last summer 2015 I seemed to lose responsiveness to Promacta, only getting to 10 on 50 mg daily. Romiplostin was no better after 3 months and was discontinued after a month on max dose as per the protocol. Rituximab was next but while waiting to start and during the 4 weeks infusions I dropped to1. At Xmas 2015 I begged to go back on Promacta as I had bleeding gums and we agreed that it was worth it to keep me above bleeding level. I was put on 75 mg daily and gradually rose to 10 again and then each month for 10 months I have kept on rising till now at 59 we are planning to lower the dose if my count rises further. ITP is indeed a very unpredictable condition and our drug responsiveness is very unpredictable too so it seems worthwhile revisiting previous meds and persevering for longer at higher doses despite low counts than some protocols suggest in order to achieve improvements.
Hal9000 wrote: rjsmyth, is your baseline count now higher / lower / the same as your baseline count before starting Nplate?
DeeDee Marie wrote: I was wondering if any of you feel that your platelets might have done better if you were never on N-Plate or Promacta?
Dee Dee
Hal9000 wrote: rjsmyth, take a look at this article and notice how 'anti-idiotypic antibodies' are thought to work in IVIG.
www.nufactor.com/FA-IG_004.aspx
Then take a look at what that type of antibodies are and that vaccines are being created.
en.wikipedia.org/wiki/Anti-idiotypic_vaccine
What do you think?
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.